DiaSorin Stock - FDA clears new Group A strep test for Liaison NES

DiaSorin secures US FDA 510(k) clearance and a CLIA waiver for its Group A Streptococcus molecular test on the Liaison NES platform, expanding its point-of-care menu. On Friday we look at the week’s move in the stock and diagnostics peers.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:06 CET. Details in the imprint.

DiaSorin (IT0003497168) reported fresh regulatory progress in the United States this week. The diagnostics group secured US FDA 510(k) clearance and a CLIA waiver for its Group A Streptococcus test on the Liaison NES point-of-care platform, according to a MarketScreener news report dated 06/19/2026.

What the FDA clearance covers

According to a report carried by MarketScreener on Friday, the US Food and Drug Administration granted both 510(k) clearance and a CLIA waiver for DiaSorin’s Group A Streptococcus molecular assay. The test runs on the Liaison NES point-of-care platform aimed at decentralized settings.

The article highlights that this is the second significant US approval for Liaison NES after clearance for a combined FLU A/B, RSV and Covid-19 assay in December 2025. The new clearance broadens the clinical menu and supports the commercial rollout of the platform in primary care and urgent-care environments.

Weekly move and diagnostics peers

DiaSorin shares in Milan traded in a relatively tight range over the week, reflecting a muted broader European diagnostics sector. Peers in molecular diagnostics also faced a mixed backdrop as investors weighed procedure volumes against pricing pressure in routine testing.

All told, the fresh US authorization gives DiaSorin an additional talking point as investors compare medium-term growth prospects against names such as bioMérieux and Roche’s diagnostics division. On balance, the week’s news flow tilts slightly positive for the fundamentals even if the share reaction stayed measured.

How DiaSorin makes its money

DiaSorin generates most of its revenue from in vitro diagnostics, with a strong focus on immunodiagnostics and molecular assays sold to hospitals and laboratories. Its portfolio includes the Liaison and Liaison NES platforms, offering automated testing for infectious diseases and other clinical indications.

Where the stock trades today

The shares of DiaSorin (IT0003497168) trade on Euronext Milan at EUR 100.00 as of 06/19/2026, 17:35 CET.

Key facts on DiaSorin stock

• Company: DiaSorin S.p.A.
• ISIN: IT0003497168
• WKN: 939952
• Ticker: DIA
• Venue: Euronext Milan
• Price (as of 06/19/2026, 17:35 CET): 100.00 EUR
• Market cap: 5,600,000,000 EUR (as of 06/19/2026)
• Sector / Industry: Health Care / Biotechnology & Medical Research
• Index membership: FTSE Italia Mid Cap
• Next earnings date: 08/02/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.